drugset
Drugs / 101-PGC-005
last change Jun 2023 re-read 3 minutes ago

101-PGC-005

also known as '005
Developed for
COVID-19
Investigated by
101 Therapeutics

Trials 3

today NCT05656521 · Ph 2 NCT05619770 · Ph 1 NCT05195749 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05619770 Oct → Nov 2022 COVID-19, poisoning 101 Therapeutics Unknown No outcome recorded
Phase 22 trials
Phase 2 NCT05656521 Jan → Apr 2023 COVID-19 101 Therapeutics Unknown No outcome recorded
Phase 2 NCT05195749 Jan 2022 → Feb 2023 COVID-19 101 Therapeutics Terminated No outcome recorded Stop: Enrollment

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as 101-PGC-005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05619770 ↗
2

NCT05195749 ↗

NCT05656521 ↗
Known as '005 “The investigational product 101-PGC-005 ('005) - a prodrug of dexamethasone that is targeted to only activated macrophages - will address the many safety and efficacy issues...” NCT05195749 ↗
Route Intravenous “administered intravenously” NCT05619770 ↗